Nada Ćujić, Svetlana Ibrić, Dubravka Bigović, Nebojša Noveski, Katarina Šavikin



In recent years, drug delivery systems are especially interesting because they allow therapeutic efficiency and reduce side effects. Conjugates of hyaluronic acid and chemotherapeutic agents, especially taxol, have been recognized as excellent solution for many therapeutic indications. The aim of conjugation of taxol with hyaluronic acid was the toxicity reduction on healthy cells and increase of selectivity on tumor cells. Hyaluronic acid could be used in various pharmaceutical preparations, also in parenteral, because of its biocompatibility and biodegradability. Hyaluronic acid as a carrier belongs to in situ gelling systems, which is passing a phase transition in response to external conditions such as temperature, different pH value or the presence of ions, enabling prolonged effect of the drug substances. Many tumor cells have a large number of receptors for hyaluronic acid, which has a great affinity for the tumor cells. The incorporation of taxol in gelling system of hyaluronic acid provides sustained drug release, increased anticancer activity, reduced damage of healthy cells and increased selectivity on cancer cells.


taxol; hyaluronic acid; in situ systems; drug delivery

Full Text:



*** (2000) Jugoslovenska farmakopeja 2000. Beograd: Savezni zavod za zaštitu i unapređenje zdravlja, Ph. Jug. V

*** (2011) European Pharmacopoeia 7.0. Strasbourg, France: European Directorate for the Quality of Medicines & HealthCare (EDQM) - Council of Europe, Vol 1. 01

*** (1996) The MerckIndex. Whitehouse Station, NJ: Merck & Co Inc, 12th Edition

*** (2009) Handbook of pharmaceutical excipients. London: Pharmaceutical Press, 6th edition

*** (2004) Guidance for industry, sterile drug products, produced by aseptic processing: Current good manufacturing practice. U.S. Department of Health and Human Services-Food and Drug Administration-Center for Drug Evaluation and Research (CDER)-Center for Biologics Evaluation and Research (CBER)-Office of Regulatory Affair

*** (2005) PDR (physicians desk references) for herbal medicines. Montvale, NJ: Medical Economics Company, Thomson, 3rd edition

Banzato, A., Bobisse, S., Rondina, M., Renier, D., Bettella, F., Esposito, G., Quintieri, L., Meléndez-Alafort, L., Mazzi, U., Zanovello, P., Rosato, A. (2008) A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clinical cancer research, 14(11): 3598-606

Cai, S., Xie, Y., Bagby, T.R., Cohen, M.S., Forrest, L.M. (2008) Intralymphatic Chemotherapy Using a Hyaluronan–Cisplatin Conjugate. Journal of Surgical Research, 147(2): 247-252

Chitkara, D., Shikanov, A., Kumar, N., Domb, A.J. (2006) Biodegradable Injectable In Situ Depot-Forming Drug Delivery Systems. Macromolecular Bioscience, 6(12): 977-990

Milić, J., Primorac, M., Stupar, M. (2005) Priručnik za vežbe iz farmaceutske tehnologije sa biofarmacijom - Sterilni lekoviti preparati. Farmaceutski fakultet, Oblast

Niazi, S.K. (2004) Handbook of pharmaceutical manufacturing formulations, Sterile products. Boca Raton: CRC Press, Vol 6; 1st edition

Packhaeuser, C., Schnieders, J., Oster, C., Kissel, T. (2004) In situ forming parenteral drug delivery systems: an overview. European Journal of Pharmaceutics and Biopharmaceutics, 58(2): 445-455

Rang, H.P., Dale, M.M., Ritter, J.M., Flower, R. (2007) Rang and Dale’s pharmacology. Elsevier Health Sciences, 6th edition

Renneberg, R. (2007) Biotech History: Yew trees, paclitaxel synthesis and fungi. Biotechnology Journal, 2(10): 1207-1209

Sweetman, S.C., ur. (2009) Martindale: The complete drug reference. London: Pharmaceutical Press

Vintiloiu, A., Leroux, J. (2008) Organogels and their use in drug delivery--a review. Journal of controlled release, 125(3): 179-92

Wen, D.Y. (2000) Intra-articular hyaluronic acid injections for knee osteoarthritis. Am Fam Physician, 62(3); 565-570

Yu, L., Ding, J. (2008) Injectable hydrogels as unique biomedical materials. Chemical Society Reviews, 37(8): 1473


  • There are currently no refbacks.

Copyright (c) 2017 Lekovite Sirovine

ISSN 0455-6224 (Print)
ISSN 2560-3965 (Online)

Creative Commons License Except where otherwise noted, the content on this site is licensed under a Creative Commons Attribution 4.0 International License.